Nagay HS, Flores MJJ, Ilarraza LH, Martínez SC, Valle ML, Tenorio LFA, Pastelín HG

Language: Spanish
References: 9
Page: 379-383
PDF size: 112.11 Kb.

ABSTRACT

Purpose: The endothelial function is the cornerstone of several cardiovascular disease. In this trial we compared how the Nitric Oxide (NO) and Oxidative Stress (OS) serum levels, as surrogate markers of endothelial function, change in patients who received (or not) rosuvastatin during the first seven days of an acute coronary syndrome (ACS). Methods: Twenty-two patients with ACS (age:66 ± 9 years, gender: ten female and 12 male) were randomized in two groups. Patients in the first group (G1) received the conventional treatment for an ACS, plus placebo. The other group (G2) additionally received a daily oral dose of 40 mg of rosuvastatin. We measured the blood levels of nitrates and OS in both groups twice: at baseline (admission to Intensive care unit) and seven days after. The statistical analysis was performed using the paired t-test or the Chi² test depending of the variables. Statistical significance was considered with a p ‹ 0.05. Results: Groups (G1 and G2) differed statistically on age (G1 = 71 years ± 10 vs G2 63 ± 9 years, p = 0.04). After 7 days of the ACS onset, ON levels diminished on 21% (p = 0.17) in G1, but raised on 24% in the group who received rosuvastatin (p = 0.005), with statistically difference between groups (p = 0.005). On the other hand, the OS, augmented statistically on both groups: G1 (17%, p ‹ 0.001) and G2 (13%, p ‹ 0.001), without any difference between groups (p = 0.77). Conclusion: The endothelial dysfunction in the first days of an ACS is accentuated, but with the use of rosuvastatina, the endothelial function improves. In contrast, the OS increase in both groups, without differences between groups.

REFERENCES

1. Canteros T, Chamorro N, Coronel C, Kippes S: Administración precoz de estatinas en el síndrome coronario agudo. Rev de Pos de la VIa Cátedra de Med 2005; 151: 17-19.

2. Pedersen TR, Kjekshus J, Berg K: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.

3. Undas A, Celinska-Löwenhoff M, Domagala TB, Iwaniec T, Dropinski J, Löwenhoff T, et al: Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost. 2005; 94 (1):193-199.

4. Li XP, Zhaos P, Li J, Li JD, Xie XM, Perg J: The effect of early fluvastatin therapy on inflammatory factors in acute coronary syndrome. Zhonghua Nei Ke Za Zhi 2005; 44(3): 184-187.

5. Stenestrand U, Wallentin L: Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-436.

6. Laufs U, La Fata V, Plutzky J, Liao JK: Up-regulation of endothelial nitric oxide synthase by HMG CoA reductas inhibitors. Circulation 1998; 97: 1129-35.

7. Tenorio LFA, del Valle ML, Pastelín HG: Validación de un método analítico espectrofotométrico para la cuantificación de metabolitos estables de óxido nítrico en fluidos biológicos. Rev Mex Cienc Farm 2005; 36(1): 31-41.

8. Bahr P, Basulto Y: El potencial redactor férrico (FRP). Un ensayo para evaluar la capacidad antioxidante en suero. Corr Cient Med Holguín 2004; 8(4): 1-7.

9. Ridker PM, Danielson E, Fonseca F, Genet J, Gotto AM, et al: Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein. New England Journal of Medicine 2008; 259: 2195-2207.